Fish oil (omega-3 fatty acid, primarily EPA and DHA) is among the most purchased dietary supplements globally — and among the most controversial in evidence-based nutrition. A $3 billion supplement market has developed around a nutrient with genuinely complex clinical evidence: clear benefits in some populations (hypertriglyceridemia, high cardiovascular risk), questionable benefits in others (general prevention), and an ongoing replication crisis in major cardiovascular outcome trials.
Cardiovascular Evidence: What the Trials Show
REDUCE-IT (2018, NEJM, n=8,179): high-dose EPA (icosapentaenoic acid only, 4g/day as Vascepa) reduced major cardiovascular events by 25% in hypertriglyceridemic patients already on statins — a landmark result driving FDA approval for cardiovascular risk reduction. Controversy: the mineral oil comparator (placebo) may have modestly increased cardiovascular events, inflating the apparent EPA benefit. The effect size is disputed. STRENGTH trial (2020, JAMA, n=13,078): high-dose EPA+DHA (4g/day as Epanova) versus corn oil comparator — no significant cardiovascular benefit. This contradicts REDUCE-IT's findings. Current interpretation: high-dose EPA-only preparation may have benefits in high-risk patients with elevated triglycerides — but standard fish oil supplements (EPA+DHA, doses of 1–3g/day) do not clearly reduce cardiovascular events in primary or secondary prevention (ASCEND, VITAL, ORIGIN trials all negative or minimally positive). Triglyceride-lowering: EPA+DHA at 3–4g/day reduces fasting triglycerides by 20–30% — well-established pharmacological effect. For this indication, prescription omega-3s are appropriate for patients with TG >500 mg/dL. For clinical nutrition management, our nutrition catalog includes clinical-grade nutritional supplements and enteral nutrition products for patients with metabolic conditions.
